At a glance
ClinicalIndex Comparison Record- ✓Age 18 to 65 years
- ✓Diagnosis of schizophrenia or schizoaffective disorder
- ✓Meets SCID criteria for substance use disorder (alcohol or drug abuse/dependence)
- ✓Active substance use on at least 8 days in the 4 weeks prior to randomization
- ✕Current treatment with depot/decanoate antipsychotics, clozapine, or non-investigator-approved quetiapine doses
- ✕Pregnant, planning pregnancy, or unwilling to use acceptable birth control
- ✕Currently residing in a residential program for substance use disorder treatment
- ✕Baseline treatment with psychotropic medication intended to reduce substance use
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia
In Brief
A Phase 4 clinical trial evaluating Quetiapine for Schizophrenia and 4 related conditions. Completed, enrolled 23 participants across 4 sites.
Detailed Summary
The purpose of this study is to examine the efficacy of quetiapine (Seroquel) in reducing substance use in persons diagnosed with schizophrenia. The primary hypothesis is that quetiapine treatment will be associated with a decrease in substance use.
Study Details
Timeline
Interventions
After patients provided informed consent and completed baseline measures, quetiapine was initiated in all participants and titrated up to a target dose of 600 mg (in divided daily doses) over two weeks as the previous antipsychotic medication was slowly tapered and discontinued. Participants met with study physicians weekly to assess tolerability and response to the medication. Concomitant medications were held constant. After the initial titration period, quetiapine was dosed in a flexible manner up to 800 mg /day, with dose adjustments based on symptomatic response and side effects.